Short-term transcriptomic response to plasma membrane injury

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Swantje Christin Häger
  • Catarina Dias
  • Stine Lauritzen Sønder
  • Olsen, André Vidas
  • Isabelle da Piedade
  • Anne Sofie Busk Heitmann
  • Elena Papaleo
  • Jesper Nylandsted

Plasma membrane repair mechanisms are activated within seconds post-injury to promote rapid membrane resealing in eukaryotic cells and prevent cell death. However, less is known about the regeneration phase that follows and how cells respond to injury in the short-term. Here, we provide a genome-wide study into the mRNA expression profile of MCF-7 breast cancer cells exposed to injury by digitonin, a mild non-ionic detergent that permeabilizes the plasma membrane. We focused on the early transcriptional signature and found a time-dependent increase in the number of differentially expressed (> twofold, P < 0.05) genes (34, 114 and 236 genes at 20-, 40- and 60-min post-injury, respectively). Pathway analysis highlighted a robust and gradual three-part transcriptional response: (1) prompt activation of immediate-early response genes, (2) activation of specific MAPK cascades and (3) induction of inflammatory and immune pathways. Therefore, plasma membrane injury triggers a rapid and strong stress and immunogenic response. Our meta-analysis suggests that this is a conserved transcriptome response to plasma membrane injury across different cell and injury types. Taken together, our study shows that injury has profound effects on the transcriptome of wounded cells in the regeneration phase (subsequent to membrane resealing), which is likely to influence cellular status and has been previously overlooked.

OriginalsprogEngelsk
Artikelnummer19141
TidsskriftScientific Reports
Vol/bind11
ISSN2045-2322
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
This study was supported by the Danish Council for Independent Research, Natural Sciences (6108-00378A, 9040-00252B) (JN, SCH, SLS), the Novo Nordisk Foundation (NNF18OC0034936) (JN, CD, ASH), the Scientific Committee Danish Cancer Society (R90-A5847-14-S2) (JN, SLS), and the Danmarks Grundforskningsfond (DNRF125).

Publisher Copyright:
© 2021, The Author(s).

ID: 281155535